BMI Cardiovascular Disease Cholesterol 
DAIC
APRIL 24, 2024
The app also recorded other significant heart health risk factors, such as cholesterol, weight, and physical activity via integration with external sources including electronic medical records and fitness trackers. Among participants with baseline body mass index (BMI) above 30 kg/m2, 70.4%
Cardiology Update
JANUARY 24, 2024
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. The post Global Trends in Cardiovascular Diseases: Insights from the 2023 Almanac appeared first on Cardiology Update. Original article: Mensah GA et al.
DAIC
MAY 21, 2024
A new peer-reviewed study published in the Journal of the American Heart Association , JAHA, found that Hello Heart’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight. statins). . - of their body weight.
Stroke Journal
FEBRUARY 1, 2024
It is currently unknown if these associations are confounded by pleiotropic effects of the instrumental variables (IV) on cardiovascular disease (CVD) risk factors, such as low-density lipoprotein cholesterol (LDL), diastolic blood pressure (DBP), and body mass index (BMI). 0.96]), or BMI (TSAT: 1.18 [1.04-1.34];
Physiologically Speaking
JANUARY 5, 2024
Exercise prevents and reverses cardiovascular disease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovascular disease (CVD) prevention and reversal.
Dr. Paddy Barrett
JANUARY 16, 2024
Cardiovascular disease, cancer and dementia account for 60% of all deaths in the US. And less diabetes means less of a driver of the three main leading causes of death - cardiovascular disease, cancer and dementia. In most developed countries as of today, NCDs account for 89% of all deaths. These are NCD’s.
Cardiometabolic Health Congress
JANUARY 3, 2024
Tirzepatide In November of 2023, the FDA approved tirzepatide (Zepbound) for chronic weight management in adults with obesity, or who are overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Expert insights. Personalized for you.
116 
Let's personalize your content